403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Satellos Bioscience Inc.
(MENAFN- Baystreet) 10:09 AM EST - Satellos Bioscience Inc.: Today announced that enrollment has been completed for BASECAMP, the company's Phase 2 clinical trial evaluating forazapadin for the treatment of Duchenne muscular dystrophy in ambulatory boys seven to 10 years of age. Satellos Bioscience Inc.
shares T are trading down $0.12 at $12.08.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment